EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling

Kanghua Li, Shuyang Mao, Xingxing Li, Huijie Zhao, Jingyi Wang, Chenyue Wang, Lisha Wu, Kunchi Zhang, Hao Yang, Mingming Jin, Zhaoli Zhou, Jin Wang und 2 weitere

Cancer Science · 2023

DOI: 10.1111/cas.15721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Kanghua Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shang…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: "Chen Guang" project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation, Construction project of Shanghai Key Laboratory of Molecular Imaging, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non–small‐cell lung cancer (NSCLC) is one of the deadliest cancers worldwide, and metastasis is considered one of the leading causes of treatment failure in NSCLC. Wnt/β‐catenin signaling is crucially involved in epithelial–mesenchymal transition (EMT), a crucial factor in promoting metastasis, and also contributes to resistance developed by NSCLC to targeted agents. Frizzled‐7 (Fzd7), a critical receptor of Wnt/β‐catenin signaling, is aberrantly expressed in NSCLC and has been confirmed to be positively correlated with poor clinical outcomes. SHH002‐hu1, a humanized antibody targeting Fzd7, was previously successfully generated by our group. Here, we studied the anti‐tumor effects of SHH002‐hu1 against NSCLC and revealed the underlying mechanism. First, immunofluorescence (IF) and near‐infrared (NIR) imaging assays showed that SHH002‐hu1 specifically binds Fzd7 + NSCLC cells and targets NSCLC tissues. Wound healing and transwell invasion assays indicated that SHH002‐hu1 significantly inhibits the migration and invasion of NSCLC cells. Subsequently, TOP‐FLASH/FOP‐FLASH luciferase reporter, IF, and western blot assays validated that SHH002‐hu1 effectively suppresses the activation of Wnt/β‐catenin signaling, and further attenuates the EMT of NSCLC cells. Finally, the subcutaneous xenotransplanted tumor model of A549/H1975, as well as the popliteal lymph node (LN) metastasis model, was established, and SHH002‐hu1 was demonstrated to inhibit the growth of NSCLC xenografts and suppress LN metastasis of NSCLC. Above all, SHH002‐hu1 with selectivity toward Fzd7 + NSCLC and the potential of inhibiting invasion and metastasis of NSCLC via disrupting Wnt/β‐catenin signaling, is indicated as a good candidate for the targeted therapy of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansAntibodiesbeta CateninCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticWnt Signaling PathwayFrizzled Receptors

Stichwörter der Autor:innen

EMTFrizzled-7NSCLCWnt/β-catenin signalingtargeted therapy

Substanzen

AntibodiesAntineoplastic Agentsbeta CateninFZD7 protein, humanFrizzled Receptors

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China.
  • School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.

ORCID-Profile: Wei Xie

Förderung

  • "Chen Guang" project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation
  • Construction project of Shanghai Key Laboratory of Molecular Imaging
  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission

Zitieren

APA

Li, K., Mao, S., Li, X., Zhao, H., Wang, J., Wang, C., Wu, L., Zhang, K., Yang, H., Jin, M., Zhou, Z., Wang, J., Huang, G., & Xie, W. (2023). Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling. Cancer Science. https://doi.org/10.1111/cas.15721

Vancouver

Li K, Mao S, Li X, Zhao H, Wang J, Wang C, et al. Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling. Cancer Science. 2023. doi:10.1111/cas.15721

BibTeX
@article{Li2023,
  author = {Li, Kanghua and Mao, Shuyang and Li, Xingxing and Zhao, Huijie and Wang, Jingyi and Wang, Chenyue and Wu, Lisha and Zhang, Kunchi and Yang, Hao and Jin, Mingming and Zhou, Zhaoli and Wang, Jin and Huang, Gang and Xie, Wei},
  title = {Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15721}
}
Kostenlos starten →